The relationship between hirudin and activated clotting time

Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery

George J. Despotis, Charles W. Hogue, Rao Saleem, Matthew Bigham, Nicholas Skubas, Ioanna Apostolidou, Assad Qayum, J. Heinrich Joist

Research output: Contribution to journalArticle

Abstract

Anticoagulation with recombinant hirudin (r-hirudin) (Refludan™) has been suggested as an alternative to heparin for patients with heparin-induced thrombocytopenia requiring cardiac surgery. We sought to develop a modified activated coagulation time (ACT) that would allow quantification of the levels of r-hirudin required during cardiopulmonary bypass (CPB). Twenty-one patients scheduled for elective cardiac surgical procedures requiring CPB were enrolled in this IRB-approved study. R-hirudin was added to blood specimens obtained before heparin administration (before CPB) and 30 min after heparin neutralization with protamine (after CPB) to result in concentrations of 0, 2, 4, 6, 7, or 8 μg/mL. Kaolin/ ACT and complete blood count measurements were assayed in native specimens (first 10 patients, Phase I) or in specimens mixed with equal volumes of commercial normal plasma (second 11 patients, Phase II). In Phase I, good (r2 = 0.83) linear relationships between ACT values and r-hirudin concentrations (≤4 μg/mL) were observed in specimens obtained before CPB. However, ACT values were markedly prolonged (P <0.0001) by r-hirudin in specimens obtained after CPB, with ACT values generally exceeding the ACT's detection limit (>999 s) at hirudin concentrations >2/ μg/mL. In patient specimens mixed with normal plasma (Phase II), ACT/hirudin relationships (i.e., hirudin/ACT slope values obtained with hirudin concentration ≤4 μg/mL) in the post-CPB period (0.022 ± 0.004 μg · mL-1 · s-1) were similar (P = 0.47) to those (0.019 ± 0.004 μg · mL-1 · s-1) obtained in the pre-CPB period. Accordingly, a significant relationship between normal plasma-supplemented ACT values and predilution hirudin concentration was obtained in the post-CPB (hirudin = 0.039ACT - 4.34, r2 = 0.91) period. Although our data demonstrate that the ACT test cannot be used to monitor hirudin during CPB, the addition of 50% normal plasma to post-CPB hemodiluted blood specimens yields a consistent linear relationship between hirudin concentration and ACT values up to a predilution concentration of 8 μg/mL. Plasma-modified ACT may be useful in monitoring hirudin anticoagulation during CPB.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalAnesthesia and Analgesia
Volume93
Issue number1
StatePublished - 2001
Externally publishedYes

Fingerprint

Hirudins
Thrombocytopenia
Thoracic Surgery
Heparin
Cardiopulmonary Bypass
Elective Surgical Procedures
Cardiac Surgical Procedures
Kaolin
Protamines
Blood Cell Count
Research Ethics Committees

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Despotis, G. J., Hogue, C. W., Saleem, R., Bigham, M., Skubas, N., Apostolidou, I., ... Joist, J. H. (2001). The relationship between hirudin and activated clotting time: Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesthesia and Analgesia, 93(1), 28-32.

The relationship between hirudin and activated clotting time : Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. / Despotis, George J.; Hogue, Charles W.; Saleem, Rao; Bigham, Matthew; Skubas, Nicholas; Apostolidou, Ioanna; Qayum, Assad; Joist, J. Heinrich.

In: Anesthesia and Analgesia, Vol. 93, No. 1, 2001, p. 28-32.

Research output: Contribution to journalArticle

Despotis, GJ, Hogue, CW, Saleem, R, Bigham, M, Skubas, N, Apostolidou, I, Qayum, A & Joist, JH 2001, 'The relationship between hirudin and activated clotting time: Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery', Anesthesia and Analgesia, vol. 93, no. 1, pp. 28-32.
Despotis, George J. ; Hogue, Charles W. ; Saleem, Rao ; Bigham, Matthew ; Skubas, Nicholas ; Apostolidou, Ioanna ; Qayum, Assad ; Joist, J. Heinrich. / The relationship between hirudin and activated clotting time : Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. In: Anesthesia and Analgesia. 2001 ; Vol. 93, No. 1. pp. 28-32.
@article{598c3d82b0a548d6942593375812dc71,
title = "The relationship between hirudin and activated clotting time: Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery",
abstract = "Anticoagulation with recombinant hirudin (r-hirudin) (Refludan™) has been suggested as an alternative to heparin for patients with heparin-induced thrombocytopenia requiring cardiac surgery. We sought to develop a modified activated coagulation time (ACT) that would allow quantification of the levels of r-hirudin required during cardiopulmonary bypass (CPB). Twenty-one patients scheduled for elective cardiac surgical procedures requiring CPB were enrolled in this IRB-approved study. R-hirudin was added to blood specimens obtained before heparin administration (before CPB) and 30 min after heparin neutralization with protamine (after CPB) to result in concentrations of 0, 2, 4, 6, 7, or 8 μg/mL. Kaolin/ ACT and complete blood count measurements were assayed in native specimens (first 10 patients, Phase I) or in specimens mixed with equal volumes of commercial normal plasma (second 11 patients, Phase II). In Phase I, good (r2 = 0.83) linear relationships between ACT values and r-hirudin concentrations (≤4 μg/mL) were observed in specimens obtained before CPB. However, ACT values were markedly prolonged (P <0.0001) by r-hirudin in specimens obtained after CPB, with ACT values generally exceeding the ACT's detection limit (>999 s) at hirudin concentrations >2/ μg/mL. In patient specimens mixed with normal plasma (Phase II), ACT/hirudin relationships (i.e., hirudin/ACT slope values obtained with hirudin concentration ≤4 μg/mL) in the post-CPB period (0.022 ± 0.004 μg · mL-1 · s-1) were similar (P = 0.47) to those (0.019 ± 0.004 μg · mL-1 · s-1) obtained in the pre-CPB period. Accordingly, a significant relationship between normal plasma-supplemented ACT values and predilution hirudin concentration was obtained in the post-CPB (hirudin = 0.039ACT - 4.34, r2 = 0.91) period. Although our data demonstrate that the ACT test cannot be used to monitor hirudin during CPB, the addition of 50{\%} normal plasma to post-CPB hemodiluted blood specimens yields a consistent linear relationship between hirudin concentration and ACT values up to a predilution concentration of 8 μg/mL. Plasma-modified ACT may be useful in monitoring hirudin anticoagulation during CPB.",
author = "Despotis, {George J.} and Hogue, {Charles W.} and Rao Saleem and Matthew Bigham and Nicholas Skubas and Ioanna Apostolidou and Assad Qayum and Joist, {J. Heinrich}",
year = "2001",
language = "English (US)",
volume = "93",
pages = "28--32",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The relationship between hirudin and activated clotting time

T2 - Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery

AU - Despotis, George J.

AU - Hogue, Charles W.

AU - Saleem, Rao

AU - Bigham, Matthew

AU - Skubas, Nicholas

AU - Apostolidou, Ioanna

AU - Qayum, Assad

AU - Joist, J. Heinrich

PY - 2001

Y1 - 2001

N2 - Anticoagulation with recombinant hirudin (r-hirudin) (Refludan™) has been suggested as an alternative to heparin for patients with heparin-induced thrombocytopenia requiring cardiac surgery. We sought to develop a modified activated coagulation time (ACT) that would allow quantification of the levels of r-hirudin required during cardiopulmonary bypass (CPB). Twenty-one patients scheduled for elective cardiac surgical procedures requiring CPB were enrolled in this IRB-approved study. R-hirudin was added to blood specimens obtained before heparin administration (before CPB) and 30 min after heparin neutralization with protamine (after CPB) to result in concentrations of 0, 2, 4, 6, 7, or 8 μg/mL. Kaolin/ ACT and complete blood count measurements were assayed in native specimens (first 10 patients, Phase I) or in specimens mixed with equal volumes of commercial normal plasma (second 11 patients, Phase II). In Phase I, good (r2 = 0.83) linear relationships between ACT values and r-hirudin concentrations (≤4 μg/mL) were observed in specimens obtained before CPB. However, ACT values were markedly prolonged (P <0.0001) by r-hirudin in specimens obtained after CPB, with ACT values generally exceeding the ACT's detection limit (>999 s) at hirudin concentrations >2/ μg/mL. In patient specimens mixed with normal plasma (Phase II), ACT/hirudin relationships (i.e., hirudin/ACT slope values obtained with hirudin concentration ≤4 μg/mL) in the post-CPB period (0.022 ± 0.004 μg · mL-1 · s-1) were similar (P = 0.47) to those (0.019 ± 0.004 μg · mL-1 · s-1) obtained in the pre-CPB period. Accordingly, a significant relationship between normal plasma-supplemented ACT values and predilution hirudin concentration was obtained in the post-CPB (hirudin = 0.039ACT - 4.34, r2 = 0.91) period. Although our data demonstrate that the ACT test cannot be used to monitor hirudin during CPB, the addition of 50% normal plasma to post-CPB hemodiluted blood specimens yields a consistent linear relationship between hirudin concentration and ACT values up to a predilution concentration of 8 μg/mL. Plasma-modified ACT may be useful in monitoring hirudin anticoagulation during CPB.

AB - Anticoagulation with recombinant hirudin (r-hirudin) (Refludan™) has been suggested as an alternative to heparin for patients with heparin-induced thrombocytopenia requiring cardiac surgery. We sought to develop a modified activated coagulation time (ACT) that would allow quantification of the levels of r-hirudin required during cardiopulmonary bypass (CPB). Twenty-one patients scheduled for elective cardiac surgical procedures requiring CPB were enrolled in this IRB-approved study. R-hirudin was added to blood specimens obtained before heparin administration (before CPB) and 30 min after heparin neutralization with protamine (after CPB) to result in concentrations of 0, 2, 4, 6, 7, or 8 μg/mL. Kaolin/ ACT and complete blood count measurements were assayed in native specimens (first 10 patients, Phase I) or in specimens mixed with equal volumes of commercial normal plasma (second 11 patients, Phase II). In Phase I, good (r2 = 0.83) linear relationships between ACT values and r-hirudin concentrations (≤4 μg/mL) were observed in specimens obtained before CPB. However, ACT values were markedly prolonged (P <0.0001) by r-hirudin in specimens obtained after CPB, with ACT values generally exceeding the ACT's detection limit (>999 s) at hirudin concentrations >2/ μg/mL. In patient specimens mixed with normal plasma (Phase II), ACT/hirudin relationships (i.e., hirudin/ACT slope values obtained with hirudin concentration ≤4 μg/mL) in the post-CPB period (0.022 ± 0.004 μg · mL-1 · s-1) were similar (P = 0.47) to those (0.019 ± 0.004 μg · mL-1 · s-1) obtained in the pre-CPB period. Accordingly, a significant relationship between normal plasma-supplemented ACT values and predilution hirudin concentration was obtained in the post-CPB (hirudin = 0.039ACT - 4.34, r2 = 0.91) period. Although our data demonstrate that the ACT test cannot be used to monitor hirudin during CPB, the addition of 50% normal plasma to post-CPB hemodiluted blood specimens yields a consistent linear relationship between hirudin concentration and ACT values up to a predilution concentration of 8 μg/mL. Plasma-modified ACT may be useful in monitoring hirudin anticoagulation during CPB.

UR - http://www.scopus.com/inward/record.url?scp=0034950011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034950011&partnerID=8YFLogxK

M3 - Article

VL - 93

SP - 28

EP - 32

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 1

ER -